8-K: Bio Green Med Preferred Stock Faces Nasdaq Delisting Warning

Bio Green Med Solution, Inc. received a Nasdaq notice for its preferred stock failing to meet the minimum $1 million market value requirement, with a compliance deadline of March 10, 2026.

Summary

• Bio Green Med Solution, Inc. (fka Cyclacel Pharmaceuticals, Inc.) received a letter from Nasdaq on September 11, 2025, regarding non-compliance of its 6% Convertible Exchangeable Preferred Stock (BGMSP).
• The Preferred Stock failed to maintain a minimum Market Value of Publicly Held Shares (MVPHS) of $1 million, as required by Nasdaq Listing Rule 5460(a)(2), for the prior 30 consecutive business days.
• The company has 180 calendar days, until March 10, 2026, to regain compliance with the MVPHS requirement for its Preferred Stock.
• During this 180-day period, the Preferred Stock will continue to trade on the Nasdaq Capital Market.
• This deficiency notice does not affect the company's Common Stock (BGMS), which also trades on the Nasdaq Capital Market.
• Compliance can be regained if the MVPHS of the Preferred Stock equals or exceeds $1 million (based on closing bid price) for a minimum of 10 consecutive business days before the deadline.
• Failure to regain compliance by March 10, 2026, will result in a delisting notification, which the company can appeal to a Nasdaq hearings panel.

Sentiment

Score: 4

Explanation: The filing indicates a negative event (delisting notice for preferred stock) but includes mitigating factors such as a compliance period and the common stock being unaffected, suggesting a moderately negative but not catastrophic immediate impact.

Positives

• The company's Common Stock (BGMS) is explicitly stated as not affected by this deficiency notice.
• A 180-calendar day period, until March 10, 2026, has been granted to regain compliance for the Preferred Stock, allowing time for corrective action.
• The Preferred Stock will continue to trade on the Nasdaq Capital Market during the compliance period.
• The company retains the right to appeal any delisting determination by Nasdaq staff.

Negatives

• The company's 6% Convertible Exchangeable Preferred Stock (BGMSP) is non-compliant with Nasdaq's minimum Market Value of Publicly Held Shares (MVPHS) requirement of $1 million.
• Failure to regain compliance by March 10, 2026, will lead to the delisting of the Preferred Stock from the Nasdaq Capital Market.

Risks

• The Preferred Stock (BGMSP) may be delisted from the Nasdaq Capital Market if the company fails to regain compliance with the $1 million MVPHS requirement by March 10, 2026.
• Inability to implement effective options to increase the MVPHS of the Preferred Stock could lead to permanent delisting.
• Potential negative investor sentiment and reduced liquidity for the Preferred Stock due to the delisting warning.

Future Outlook

The company intends to actively evaluate and monitor the Market Value of Publicly Held Shares (MVPHS) of its Preferred Stock between now and March 10, 2026, and will consider implementing various available options if the Preferred Stock does not trade at a level likely to regain compliance.

Management Comments

• We intend to actively evaluate and monitor the MVPHS of our Preferred Stock and consider implementation of various options available to the Company if the Preferred Stock does not trade at a level that is likely to regain compliance.

Industry Context

Nasdaq listing rules, such as the minimum Market Value of Publicly Held Shares (MVPHS) requirement, are standard for maintaining a public listing and ensure a certain level of liquidity and market interest in a company's securities. Non-compliance often triggers a review period, during which companies must demonstrate their ability to meet these standards or face delisting.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Preferred shareholders (BGMSP) face the risk of their shares being delisted, potentially impacting liquidity and market value.
• Common shareholders (BGMS) are explicitly stated as not being directly affected by this specific delisting notice.
• The company's management and board are tasked with actively monitoring and addressing the compliance issue to prevent delisting of the Preferred Stock.

Next Steps

• Actively evaluate and monitor the Market Value of Publicly Held Shares (MVPHS) of the Preferred Stock.
• Consider implementation of various options to regain compliance if the Preferred Stock's trading level is insufficient.
• Potentially appeal any delisting determination by Nasdaq staff if compliance is not regained by the deadline.

Key Dates

Recommendation

While the company's preferred stock (BGMSP) faces a delisting warning from Nasdaq due to failing the minimum market value requirement, the common stock (BGMS) is explicitly stated as unaffected by this notice. The company has a 180-day period to regain compliance for its preferred stock, and the ability to appeal any delisting decision. Investors should monitor the company's efforts to address the preferred stock's compliance issue, but for the common stock, this specific event does not warrant an immediate change in investment stance.

Keywords

Bio Green Med Solution, BGMS, BGMSP, Nasdaq, delisting, preferred stock, market value, compliance, SEC filing, 8-K